Elopag-50mg-Eltrombopag

 Eltrombopag Price

The price of eltrombopag can vary depending on the dosage form, the number of tablets, and your insurance coverage. However, it can be expensive, costing several thousand dollars per month.

But Elopag-50mg is cheaper than any other version of Eltrombopag and it has similar efficiency. To order  Elopag-50mg contact with us.

Approval of Eltrombopag by FDA

Eltrombopag is approved by the US Food and Drug Administration (FDA) for the treatment of:

• Chronic idiopathic thrombocytopenic purpura (ITP) in adults and children 1 year of age and older
• Primary immune thrombocytopenia (PITP) in adults and children 1 year of age and older
• Chronic hepatitis C (CHC)-associated thrombocytopenia in adults
• Refractory severe aplastic anemia (SAA) in adults

Eltrombopag was first approved by the FDA in 2008 for the treatment of ITP. It was subsequently approved for the treatment of PITP in 2011, CHC-associated thrombocytopenia in 2013, and SAA in 2015.  (6)

Eltrombopag in Dengue

Eltrombopag, a thrombopoietin receptor agonist, is being explored as a potential treatment for dengue fever, a mosquito-borne viral infection that can cause severe bleeding. It works by stimulating platelet production in the bone marrow, increasing platelet counts and reducing bleeding risk. Clinical trials have shown promising results, with one trial showing erombopaglt’s effectiveness in increasing platelet counts and reducing bleeding risk. However, more research is needed to confirm its safety and efficacy.Elopag-50mg is not currently approved by the US FDA for dengue fever treatment, but it is being used in countries where it is available due to the lack of other effective treatments. Side effects include diarrhea, nausea, headache, liver damage, and heart problems.

Eltrombopag in Aplastic Anemia

Elopag-50mg is a thrombopoietin receptor agonist (TPO-RA) that is used to treat aplastic anemia, a rare blood disorder that causes the bone marrow to produce too few blood cells. It works by stimulating the production of platelets in the bone marrow. This can help to increase platelet counts and reduce the risk of bleeding in patients with aplastic anemia.

Eltrombopag Myelodysplastic Syndrome

Clinical trials have evaluated the safety and efficacy of Elopag-50mg in treating MDS patients. However, the results have been mixed, with some trials showing it increases platelet counts but doesn’t improve overall survival. Another trial showed it reduces platelet transfusion need, but more research is needed. Elopag-50mg is not approved by the FDA for MDS treatment, but it is used in some countries due to the lack of other effective treatments. It is generally well-tolerated but can cause side effects like diarrhea, nausea, fatigue, headache, cough, rash, liver damage, heart problems, bleeding, and allergic reactions.

Eltrombopag Clinical trials

Eltrombopag has been studied in a number of clinical trials, including trials in patients with ITP, PITP, CHC-associated thrombocytopenia, refractory SAA, and dengue fever. Results from these trials have shown that eltrombopag is an effective and safe treatment for these conditions.

Here are some examples of eltrombopag clinical trials:

• ITP: A Phase III clinical trial in patients with ITP showed that Elopag-50mgwas more effective than placebo in increasing platelet counts and reducing the risk of bleeding.
• PITP: A Phase III clinical trial in patients with PITP showed that Elopag-50mg was more effective than placebo in increasing platelet counts and reducing the risk of bleeding.
• CHC-associated thrombocytopenia: A Phase III clinical trial in patients with CHC-associated thrombocytopenia showed that Elopag-50mg was more effective than placebo in increasing platelet counts and reducing the risk of bleeding.
• Refractory SAA: A Phase II clinical trial in patients with refractory SAA showed that Elopag-50mgincreased platelet counts to safe levels in 75% of patients.
• Dengue fever: A Phase II clinical trial in patients with severe dengue fever showed that Elopag-50mg was effective in increasing platelet counts and reducing the risk of bleeding.

Eltrombopag brand name

The brand name of eltrombopag is Promacta. It is available as a tablet and oral suspension.

Promacta is manufactured by Novartis Pharmaceuticals Corporation and is marketed in the United States and Canada. It is also marketed in other countries under the brand name Revolade.

See our other Products Elbonix-25, Avalet-20mg, Palbonix100/125mg, Ventoxen-100mg, Ibruxen-140mg.